Reuters ahead on key Amgen drug news, shares rise

Shares of Amgen, the world’s biggest biotechnology company, rose as much as 3.6 percent on August 11 after Reuters reported U.S. regulators’ view of the company’s most important drug candidate. Reuters sent headlines on a Food and Drug Administration report that listed infections and other issues as the main safety concerns for osteoporosis drug Denosumab. Amgen shares rose as the safety issues were known to investors and were viewed as unlikely to stall approval of the drug. Reuters reported three key points from the FDA analysis of denosumab before Bloomberg’s first headline, which was nearly three minutes behind Reuters. Dow Jones followed Reuters by 15 minutes.